The researchers identified molecular subtypes of head and neck cancer that could be susceptible to CDK inhibitor, anti-EGFR antibody, or immunotherapy treatments.
Through this partnership, the companies hope to help oncologists make better testing and treatment decisions, as well as improve clinical trial matching.
The partners are starting by testing patients with colorectal and thyroid cancers using the 648-gene Tempus xT assay, but could expand to other areas in the future.
The company hopes the data will help convince clinicians to adopt the algorithm in CRC as it pushes forward validations for other areas like pancreatic and ovarian tumors.
